Osteonecrosis de los maxilares por bisfosfonatos. Actualización y puesta al día

Autores/as

  • F. Cardona Tortajada
  • J.V. Bagán Sebastián
  • E. Sainz Gómez
  • J. Figuerido Garmendia
  • F. Giner Muñoz
  • F. J. Vidán Lizari

DOI:

https://doi.org/10.23938/ASSN.0138

Palabras clave:

Bisfosfonatos. Difosfonatos. Osteonecrosis mandibular. Osteoporosis. Cirugía bucal

Resumen

Los bisfosfonatos son unos fármacos ampliamente utilizados principalmente para la osteoporosis y también en oncología. Un efecto secundario o complicación de los mismos, desconocida hasta el año 2003, es la osteonecrosis de los maxilares. Se revisan, en este trabajo, las características químicas de los distintos bisfosfonatos, su posible mecanismo de acción, la potencia relativa, los productos comerciales existentes en el mercado farmacéutico español y sus indicaciones; igualmente se repasa la osteonecrosis de los maxilares en sus comienzos, su concepto, sus estadios clínicos, la razón por la que esta patología aparece en los maxilares, sus factores de riesgo, su incidencia, la actitud a tomar por los dentistas con los pacientes que toman bisfosfonatos, el tratamiento y la posible predicción de la osteonecrosis.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

1. LICATA AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005; 39: 668-677.

https://doi.org/10.1345/aph.1E357

2. CHAIAMNUAY S, SAAG KG. Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates? Rev Endocr Metab Disord 2006; 7: 101-112.

https://doi.org/10.1007/s11154-006-9008-y

3. MERIGO E, MANFREDI M, MELETI M, CORRADI D, VESCOVI P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronato): a four-case report. J Oral Pathol Med 2005; 34: 613-617.

https://doi.org/10.1111/j.1600-0714.2005.00351.x

4. MALDEN N, BELTES C, LOPES V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br Dent J 2009; 206: 93-98.

https://doi.org/10.1038/sj.bdj.2009.5

5. ROGERS MJ. From molds and macrophages to mavelonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004; 75: 451-461.

https://doi.org/10.1007/s00223-004-0024-1

6. LIN JH, RUSSELL G, GERTZ B. Pharmacokinetics of alendronato: an overview. Int J Clin Pract (Suppl.) 1999; 101: 18-26.

7. ALONCI A, ALLEGRA A, BELLOMO G, QUARTARONE E, OTERI G, NASTRO E et al. Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1. Leuk Lymphoma 2007; 48: 1852-1854.

https://doi.org/10.1080/10428190701509806

8. OTERI G, ALLEGRA A, BELLOMO G, ALONCI A, NASTRO E, PENNA G et al. Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration. Cytokine 2008; 43: 103-104.

https://doi.org/10.1016/j.cyto.2008.05.010

9. KING AE, UMLAND EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008; 28: 667-677.

https://doi.org/10.1592/phco.28.5.667

10. HELLSTEIN JW, MAREK CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005; 63: 682-689.

https://doi.org/10.1016/j.joms.2005.01.010

11. WATTS NB. Treatment of osteoporosis with bisphosphonates. Endocrinol Metab Clin North Am 1998; 27: 419-439.

https://doi.org/10.1016/S0889-8529(05)70014-1

12. RUGGIERO SL, DODSON TB, ASSAEL LA, LANDESBERG R, MARX RE, MEHROTRA B. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009; 67 (Suppl. 1): 2-12.

https://doi.org/10.1016/j.joms.2009.01.009

13. LIN JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75-85.

https://doi.org/10.1016/8756-3282(95)00445-9

14. FLEISCH H, RUSSELL RG, BISAZ S, CASEY PA, MÜHLBAUER RC. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcif Tissue Res 1968; (Suppl.): 10-10a.

https://doi.org/10.1007/BF02065192

15. RUSSELL RG, SMITH R. Diphosphonates. Experimental and clinical aspects. J Bone Joint Surg Br 1973; 55: 66-86.

https://doi.org/10.1302/0301-620X.55B1.66

16. SHEPPARD H, UTTLEY WS, SYME J, BELTON N. Proceedings: use of diphosphonates in diseases associated with ectopic calcification. Arch Dis Child 1974; 49: 828.

https://doi.org/10.1136/adc.49.10.828-b

17. MUNDY GR, YONEDA T. Bisphosphonates as anticancer drugs. N Engl J Med 1998; 339: 398-400.

https://doi.org/10.1056/NEJM199808063390609

18. SEDGHIZADEH PP, STANLEY K, CALIGIURI M, HOFKES S, LOWRY B, SHULER CHF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw An institutional inquiry. J Am Dent Assoc 2009; 140: 61-66.

https://doi.org/10.14219/jada.archive.2009.0019

19. VAN DEN WYNGAERT T, HUIZING MT, FOSSION E, VERMORKRN JB. Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist 2009; 14: 181-191.

https://doi.org/10.1634/theoncologist.2008-0209

20. Agencia Española de Medicamentos y Productos Sanitarios [consultado 28-06-2009] Disponible en:

https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm

21. MARX RE, SAWATARI Y, FORTIN M, BROUMAND V. Bisphosphonate-induced exponed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005; 63: 1567-1575.

https://doi.org/10.1016/j.joms.2005.07.010

22. BLACK DM, DELMAS PD, EASTELL R, REID IR, BOONEN S, CAULEY JA et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.

https://doi.org/10.1056/NEJMoa067312

23. GRBIC JT, LANDESBERG R, LIN SQ, MESENBRINK P, REID IR, LEUNG PCH et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronica acid once yearly pivotal fracture trial. J Am Dent Assoc 2008; 139: 32-40.

https://doi.org/10.14219/jada.archive.2008.0017

24. MARX RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemia. J Oral Maxillofac Surg 2003; 61: 1115-1118.

https://doi.org/10.1016/S0278-2391(03)00720-1

25. RUGGIERO SL, MEHROTRA B, ROSENBERG TJ, ENGROFF SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.

https://doi.org/10.1016/j.joms.2004.02.004

26. BAGAN JV, MURILLO J, JIMENEZ Y, POVEDA R, MILIAN MA, SANCHIS JM et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005; 34: 120-123.

https://doi.org/10.1111/j.1600-0714.2004.00269.x

27. SCHWARTZ HC. Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg 2004; 62: 763-764.

https://doi.org/10.1016/j.joms.2004.03.005

28. PASTOR-ZUAZAGA D, GARATEA-CRELGO J, MARTINO-GORBEA R, ETAYO-PÉREZ A, SEBASTIÁN-LÓPEZ C. Osteonecrosis of the jaws and bisphosphonates. Report of three cases. Med Oral Patol Oral Cir Bucal 2006; 11: E76-79.

29. BAGÁN JV, DIZ DIOS P, GALLEGO L, INFANTE-COSSÍO P, JIMÉNEZ Y, JUNQUERA LM et al. Recomendaciones para la prevención de la osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos intravenosos. Med Oral Patol Oral Cir Bucal 2008; 13 (Supl. 3): 161-167.

30. BAGAN JV, JIMÉNEZ Y, DIAZ JM, MURILLO J, SANCHIS JM, POVEDA R et al. Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification. Oral Oncol 2009; 45: 645-646.

https://doi.org/10.1016/j.oraloncology.2008.05.011

31. WOO SB, HELLSTEIN JW, KALMAR JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-761.

https://doi.org/10.7326/0003-4819-144-10-200605160-00009

32. MIGLIORATI CA, CASIGLIA J, EPSTEIN J, JACOBSEN PL, SIEGEL MA, WOO SB. Managing the care of patients with bisphosphonate associated osteonecrosis An American Academy of Oral Medicine position paper. J Am Dent Assoc 2005; 136: 1658-1668.

https://doi.org/10.14219/jada.archive.2005.0108

33. SARASQUETE ME, GARCÍA-SANZ R, MARÍN L, ALCOCEBA M, CHILLÓN MC, BELANZATEGUI A et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism análisis. Blood 2008; 112: 2709-2712.

https://doi.org/10.1182/blood-2008-04-147884

34. CARTSOS VM, ZHU S, ZAVRAS AI. Bisphosphonate use and the risk of adverse jaw outcomes. A medical claims study of 714,217 people. J Am Dent Assoc 2008; 139: 23-30.

https://doi.org/10.14219/jada.archive.2008.0016

35. BAGAN J, SCULLY C, SABATER V, JIMÉNEZ Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ); A concise update. Oral Oncol 2009; 45: 551-554.

https://doi.org/10.1016/j.oraloncology.2009.01.002

36. KHAN AA, SÁNDOR GKB, DORE E, MORRISON AD, ALSAHLI M, AMIN F et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009; 36: 478-490.

https://doi.org/10.3899/jrheum.080759

37. KHOSLA S, BURR D, CAULEY J, DEMPSTER DW, EBELING PR, FELSENBERG D et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the american society for bone and mineral research. J Bone Miner Res 2007; 22: 1479-1491.

https://doi.org/10.1359/jbmr.0707onj

38. DIMOPOULOS MA, KASTRITIS E, BAMIA C, MELAKOPOULOS I, GIKA D, ROUSSOU M et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20: 117-120.

https://doi.org/10.1093/annonc/mdn554

39. RIPAMONTI CI, MANIEZZO M, CAMPA T, FAGNONI P, BRUNELLI C, SAIBENE G et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20: 137-145.

https://doi.org/10.1093/annonc/mdn526

40. EDWARDS BJ, HELLSTEIN JW, JACOBSON PL, KALTMAN S, MARIOTTI A, MIGLIORATI CA et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy. An advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008; 139: 1674-1677.

https://doi.org/10.14219/jada.archive.2008.0110

41. NASTRO E, MUSOLINO C, ALLEGRA A, OTERI G, CICCIÙ M, ALONCI A et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol 2007; 117: 181-187.

https://doi.org/10.1159/000097876

42. MARX RE, CILLO JE, ULLOA JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397-2410.

https://doi.org/10.1016/j.joms.2007.08.003

43. BAGAN JV, JIMÉNEZ Y, GÓMEZ D, SIRERA R, POVEDA R, SCULLY C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 2008; 44: 1088-1089.

https://doi.org/10.1016/j.oraloncology.2008.01.012

44. BAIM S, MILLER PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009; 24: 561-574.

https://doi.org/10.1359/jbmr.090203

45. DON-WAUCHOPE A, COLE DEC. The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw. Clin Biochem 2009; 42: 1194-1196.

https://doi.org/10.1016/j.clinbiochem.2009.02.014

Descargas

Publicado

13-01-2010

Cómo citar

1.
Cardona Tortajada F, Bagán Sebastián J, Sainz Gómez E, Figuerido Garmendia J, Giner Muñoz F, Vidán Lizari FJ. Osteonecrosis de los maxilares por bisfosfonatos. Actualización y puesta al día. An Sist Sanit Navar [Internet]. 13 de enero de 2010 [citado 6 de diciembre de 2025];32(3):423-37. Disponible en: https://recyt.fecyt.es/index.php/ASSN/article/view/7225

Número

Vol. 32 Núm. 3 (2009)

Sección

Revisiones

Licencia

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.

La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.

Artículos similares

1 2 3 4 5 6 7 8 9 10 > >> 

También puede Iniciar una búsqueda de similitud avanzada para este artículo.